

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>INCANNEX HEALTHCARE LIMTIED</b>
<b>ABN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Joel Latham
<b>Date of last notice</b>	12 August 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	2 June 2023
<b>No. and class of securities held prior to change</b>	<ul style="list-style-type: none"><li>• 18,097,541 IHL ordinary shares</li><li>• 2,850,872 IHL ordinary shares escrowed until 30.06.2023</li><li>• 1,866,667 IHL ordinary shares escrowed until 30.06.2024</li><li>• 933,334 IHL ordinary shares escrowed until 30.06.2025</li><li>• 1,500,000 unlisted \$0.05 options expiring 30.06.2025</li><li>• 750,000 unlisted \$0.05 options expiring 30.06.2026</li><li>• 750,000 unlisted \$0.05 options expiring 30.06.2026 (ESC)</li><li>• 1,500,000 unlisted \$0.05 options expiring 30.06.2027 (ESC)</li><li>• 1,866,666 unlisted \$0.26 options expiring 01.05.2025</li><li>• 1,866,666 unlisted \$0.31 options – vesting 30.06.2023 and expiring 01.05.2026</li><li>• 1,866,668 unlisted \$0.35 options– vesting 30.06.2024 and expiring 01.05.2027</li></ul>
<b>Number acquired</b>	1,583,227 unlisted \$0.25 options expiring on 30 April 2026

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$1,583.23
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>• 18,097,541 IHL ordinary shares</li> <li>• 2,850,872 IHL ordinary shares escrowed until 30.06.2023</li> <li>• 1,866,667 IHL ordinary shares escrowed until 30.06.2024</li> <li>• 933,334 IHL ordinary shares escrowed until 30.06.2025</li> <li>• 1,500,000 unlisted \$0.05 options expiring 30.06.2025</li> <li>• 750,000 unlisted \$0.05 options expiring 30.06.2026</li> <li>• 750,000 unlisted \$0.05 options expiring 30.06.2026 (ESC)</li> <li>• 1,500,000 unlisted \$0.05 options expiring 30.06.2027 (ESC)</li> <li>• 1,866,666 unlisted \$0.26 options expiring 01.05.2025</li> <li>• 1,866,666 unlisted \$0.31 options – vesting 30.06.2023 and expiring 01.05.2026</li> <li>• 1,866,668 unlisted \$0.35 options– vesting 30.06.2024 and expiring 01.05.2027</li> <li>• 1,583,227 unlisted \$0.25 options expiring on 30 April 2026</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Purchase of Loyalty Options

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>INCANNEX HEALTHCARE LMTIED</b>
<b>ABN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Peter Widdows
<b>Date of last notice</b>	21 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	The Peter Widdows Superannuation Fund (Beneficiary)
<b>Date of change</b>	2 June 2023
<b>No. and class of securities held prior to change</b>	<b>DIRECT</b> <ul style="list-style-type: none"><li>15,973,685 IHL ordinary shares</li></ul> <b>INDIRECT</b> <ul style="list-style-type: none"><li>600,0000 IHL ordinary shares</li></ul>
<b>Number acquired</b>	<b>DIRECT</b> <ul style="list-style-type: none"><li>1,064,913 unlisted \$0.25 options expiring on 30 April 2026</li></ul> <b>INDIRECT</b> <ul style="list-style-type: none"><li>40,000 unlisted \$0.25 options expiring on 30 April 2026</li></ul>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$1,104.92

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<p>DIRECT</p> <ul style="list-style-type: none"> <li>15,973,685 IHL ordinary shares</li> <li>1,064,913 unlisted \$0.25 options expiring on 30 April 2026</li> </ul> <p>INDIRECT</p> <ul style="list-style-type: none"> <li>600,000 IHL ordinary shares</li> <li>40,000 unlisted \$0.25 options expiring on 30 April 2026</li> </ul>
<p><b>Nature of change</b></p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Purchase of Loyalty Options

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<p><b>No. and class of securities to which interest related prior to change</b></p> <p>Note: Details are only required for a contract in relation to which the interest has changed</p>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<p><b>Value/Consideration</b></p> <p>Note: If consideration is non-cash, provide details and an estimated valuation</p>	
<b>Interest after change</b>	

## Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
--	-----

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>INCANNEX HEALTHCARE LMTIED</b>
<b>ABN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Troy Valentine
<b>Date of last notice</b>	12 August 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	See notes below
<b>Date of change</b>	2 June 2023
<b>No. and class of securities held prior to change</b>	<ul style="list-style-type: none"><li>36, 651 198 IHL Ordinary Shares</li><li>2,800,000 Options with various exercise prices, vesting dates and expiry dates.</li></ul>
<b>Number acquired</b>	<ul style="list-style-type: none"><li>2,443,413 unlisted \$0.25 options expiring on 30 April 2026</li></ul>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$2,443.41
<b>No. of securities held after change</b>	<ul style="list-style-type: none"><li>36, 651 198 IHL Ordinary Shares</li><li>2,800,000 Options with various exercise prices, vesting dates and expiry dates.</li><li>2,443,413 unlisted \$0.25 options expiring on 30 April 2026</li></ul>

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Purchase of Loyalty Options
---	-----------------------------

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.



**Notes – Direct & Indirect Interests**

**(a) Description of entities/relationships:**

1. Troy Valentine is:
  - a. A beneficiary of the GFCR Investments Trust, the FT Family Trust, and the Troy R Valentine Superfund;
  - b. A director of Tranaj Nominees Pty Ltd, Valplan Pty Ltd, Alignment Capital Pty Ltd and Cityside Pty Ltd
  - c. 100% shareholder in Cityside Pty Ltd (ACN 112 375 354)(“**Cityside**”)
  - d. 50% shareholder in Alignment Capital Pty Ltd (ACN 167 124 754)(“**Alignment**”)
2. Ekirtson Nominees Pty Ltd (ACN 137 521 825) is trustee for the GFCR Investments Trust (“**Ekirtson**”)
3. Tranaj Nominees Pty Ltd (ACN 137 521 843) is trustee of the FT Family Trust (“**Tranaj**”)
4. Valplan Pty Ltd (ACCN 135 269 169) is trustee of the Troy R Valentine Family Superfund (“**Valplan**”)

**(b) Table 1 – holdings before changes**

	<b>IHL Ordinary Shares</b>	<b>IHL Options</b>
Troy Valentine	2,925,000 <sup>^</sup>	2,800,000 <sup>^^</sup>
Ekirtson *	2,875,000	
Tranaj *	10,216,950	
Valplan	3,000,000	
Alignment *	13,194,248	
Cityside	4,440,000	
<b>TOTAL</b>	<b>36,651,198</b>	

**(c) Table 2 – holdings after changes**

	<b>IHL Ordinary Shares</b>	<b>IHL Options</b>
Troy Valentine	2,925,000 <sup>^</sup>	2,994,999 <sup>^^</sup>
Ekirtson *	2,875,000	191,667
Tranaj *	10,216,950	681,130
Valplan	3,000,000	200,000
Alignment *	13,194,248	879,617
Cityside	4,440,000	296,000
<b>TOTAL</b>	<b>36,651,198</b>	<b>5,243,413</b>

\* Mr Valentine is not the sole beneficiary of these entities.

<sup>^</sup> Of these 2,333,334 Securities issued to KMP as part of remuneration package for FY 21 and 22, subsequent to Shareholder Approval obtained at the General Meeting of the Company on 09 June 2022; with vesting dates as per details in the Notice of Meeting dated 12 May 2022. 466,666 Shares have already vested.

<sup>^^</sup> Securities issued to KMP as part of remuneration package for FY 21 and 22, subsequent to Shareholder Approval obtained at the General Meeting of the Company on 09 June 2022; with vesting dates as per details in the Notice of Meeting dated 12 May 2022.

---

+ See chapter 19 for defined terms.